You are using an outdated browser. Please upgrade your browser to improve your experience and security.

Patient Profiles—Planning For Success

The following profiles are of hypothetical PAH patients and their experiences starting with Remodulin. These have been developed to help you determine the best course of action and find different strategies for managing patients on Remodulin.

Gail – Reaching Optimal Dose

63 years old | Married | Cafeteria worker

Plans to retire within the next 2 years to travel
Enjoys road trips with her husband in their recreational vehicle
Often needs to catch her breath at work or when setting up camp

6-Month Follow-Up

After 6 months of oral combination therapy, Gail’s condition has declined (reduced 6MWD, increased RAP, and septal flattening; REVEAL 2.0 score: 9). Her PAH specialist recommends adding Remodulin. In order to achieve the best outcomes, Gail’s PAH specialist implements specific strategies for success.

Medical History

Diagnosed with iPAH 6 months ago based on RHC, intermediate-risk status (REVEAL 2.0 score: 7)^1,2
Prescribed an oral combination therapy regimen (PDE-5i and ERA) after diagnosis³

Strategies for Success: The Right Pump, the Right Dose, and the Right Plan

Gail is hesistant to go on pump therapy but her symptoms are getting worse. She and her PAH specialist talk through her concerns and Gail agrees to try Remodulin.

Gail’s PAH specialist trusts Remodulin because it is the #1 prescribed parenteral therapy for PAH, with a long history of clinical success^4,5

Together, they decide on SC Remodulin because Gail wants:

A pump that is lightweight and easy to carry

To avoid the possibility of infusion-related bloodstream infections associated with IV therapy⁴

The flexibility to start her therapy at home

The peace of mind that she will be supported during her journey

With Remodulin, I am able to be more active. It’s so helpful that my pump is small enough that I can carry it around and get on with my life.

—Gail

View more information about the benefits of SC Remodulin.

Learn More

Improvement in 6MWD⁶

Real-world rapid-titration experience over 24 months

In a retrospective study, patients who achieved an SC Remodulin dose of at least 20 ng/kg/min at 3 months demonstrated significant and durable improvements in 6MWD over time.⁶*

*Clinical outcomes, including 6MWD, were analyzed in an open-label, multicenter retrospective study of 122 patients with pulmonary hypertension.⁶

^†Remodulin dose, site pain, and site changes were analyzed in a 1-year, diary-based, prospective study of 26 patients on SC Remodulin.⁷

View more information on the dosing and administration of Remodulin.

Learn More

Ensure understanding of potential AEs and proper infusion site management

Use preferred infusion sites⁸

Rotate sites infrequently (>4 weeks)⁷

Know when to change infusion sites⁷

Consider adding a pain management plan that includes analgesics and other local, topical, or systemic therapies as needed^7,8
Add standing orders for AE management in the referral form to ensure SP alignment on support
Confirm that patients know who to contact if they experience an AE (ie, their care team, their SP nurse)

United Therapeutics does not provide medical advice. Side-effect management strategies should be dealt with in accordance with the Remodulin Full Prescribing Information and your clinical judgment.

View more information on proactively managing adverse events.

CREATE A PLAN

Gail’s 9-Month Follow-Up

In the 3 months since starting SC Remodulin, Gail reports that she feels like she can be more active and doesn’t have to catch her breath as often.

Risk Assessment

Risk Variables^1,2	At Diagnosis	6-Month Follow-Up (PDE-5i and ERA)	9-Month Follow-up (SC Remodulin, PDE-5i, and ERA)
WHO FC	III	III	III
6MWD	265	245	375
NT-proBNP (ng/L)	980	1020	770
REVEAL 2.0 score	7	9	5

Other inputs aside from those listed here were incorporated in REVEAL 2.0 score.

I still get site pain after rotating sites, but now I’m able to manage it.

—Gail

How could you integrate these strategies to set your patients up for success when starting Remodulin?

View more information on dosing for Remodulin.

Learn More

6MWD=6-minute walk distance; AE=adverse event; ERA=endothelin receptor antagonist; FC=functional class; iPAH=idiopathic pulmonary arterial hypertension; IV=intravenous; NT-proBNP=N-terminal pro–B-type natriuretic peptide; PAH=pulmonary arterial hypertension; PDE-5i=phosphodiesterase type 5 inhibitor; RAP=right atrial pressure; REVEAL=Registry to Evaluate Early and Long-Term PAH Disease Management; RHC=right heart catheterization; SC=subcutaneous; SP=Specialty Pharmacy; WHO=World Health Organization.

Charlotte – Switching From IV To SC

47 years old | Divorced | Small business owner

Is part owner of her own electrical business
Enjoys puzzles and strategy games
Experiences frequent shortness of breath on job sites

Medical History

Charlotte was rushed to the ER after fainting on a job site. She was eventually diagnosed with PAH. Due to high-risk status, she was prescribed a combination therapy regimen including IV prostacyclin.¹ She started IV infusion of Remodulin at the hospital, but transitioned to SC Remodulin upon discharge.

Strategies For Success: How An AE Management Strategy Can Help Transform Experiences With Infusion Site Pain

SC is the preferred route of administration because of the risk of bloodstream infections and sepsis associated with IV infusions²
Proper transition protocols prevent interruptions in drug delivery while maintaining therapeutic benefit and minimizing AEs²

SC and IV Remodulin: Bioavailable within minutes and bioequivalent in <6 hours^2,3*

Real-world bioavailable experience over 24 months

Figure adapted from Laliberte K, et al. Cardiovasc Pharmacol. 2004, with permission.

View more information about the benefits of SC Remodulin.

Learn More

Charlotte’s 3-Month Follow-Up

In the 3 months since transitioning to SC Remodulin, Charlotte reports improvements in PAH symptoms, but she is experiencing severe site pain and is on the verge of discontinuing. Charlotte and her PAH specialist discuss strategies to help manage her infusion site pain while achieving her treatment goals, and Charlotte agrees to stay on SC Remodulin.

My site pain is so intense that on some days I can barely walk—much less be effective at running a business. If this pain continues, I’m going to have to stop therapy.

—Charlotte

In a retrospective study of 811 patients receiving SC Remodulin, higher doses correlated with better prognosis^4†
- Patients were enrolled in randomized, placebo-controlled trials from 1999 to 2003
- Most patients were FC III (76%), and 23% of patients were on concomitant PAH medications
- Patients were followed for as long as they received Remodulin and were censored at the time of discontinuation

Remodulin dose and site pain were not shown to be correlated (n=26)^5‡

Real-world infusion-site-pain experience over 24 months

Lowering the dose of SC Remodulin may not be associated with a decrease in site pain.⁵

Data from retrospective analysis should be interpreted with appropriate caution.

*Remodulin pharmacokinetics were analyzed at steady state in 51 healthy volunteers randomized to receive IV or SC Remodulin at a dose of 10 ng/kg/min. Patients received one route of administration during the first 72-hour dosing period, and the alternate route during dosing period 2.³

^†In a multivariate analysis, every 10 ng/kg/min dose increase resulted in improved long-term survival.⁴

^‡Remodulin dose, site pain, and site changes were analyzed in a 1-year, diary-based, prospective study of 26 patients on SC Remodulin.⁵

Consider discussing proper infusion site selection and rotation procedures as needed

Best administration sites for Remodulin IV and SC

Site pain intensity is generally highest in the first few days after changing a site; rotating sites infrequently (>4 weeks) can reduce the frequency of initial site pain⁵

Add standing orders for AE management in the referral form to ensure SP alignment on support
Engage with the patient about how they are managing their site. Questions may include:
- How often are you changing sites?
- How do you decide when a site rotation is required?
- Are you using a dry site approach?
- Have you tried different cannulas/setters?

By asking questions, her PAH specialist discovered that Charlotte was changing her site weekly without numbing the site. Charlotte’s physician discussed options such as a topical anesthetic when initiating a new site, and advised her to rotate her site only if she was experiencing ongoing site pain, itching, erythema, drainage, or bleeding.^5,6

Learn more about AE management.

CREATE A PLAN

Charlotte’s 6-Month Follow-Up

At her 6-month follow-up, Charlotte reported that her site pain was more tolerable. Although still at intermediate-risk status, her 6MWD and NT-proBNP levels continue to show improvement while on SC Remodulin.

In the last few months, I’ve learned so much. If I follow the plan my doctor gave me, it helps me manage my pain enough that it doesn’t interfere with my life. Plus, my SP nurse has given me helpful tips on how to manage my pump and my site pain. What a difference support can make!

—Charlotte

How could you integrate these strategies into your current approach to set your patients up for success with SC Remodulin?

View more information on how to manage AEs for patients on Remodulin.

Learn More

6MWD=6-minute walk distance; AE=adverse event; FC=functional class; IV=intravenous; NT-proBNP=N-terminal pro–B-type natriuretic peptide; PAH=pulmonary arterial hypertension; SC=subcutaneous; SP=Specialty Pharmacy.

HOW THE REMUNITY^® PUMP FITS INTO PATIENTS’ LIVES

The Remunity Pump for Remodulin may be appropriate for patients seeking a small, simple, and safe way to discreetly manage their PAH symptoms. Below are profiles of hypothetical patients and their experiences using the Remunity pump.

MIRANDA – LOOKING FOR A SAFE, MODERN PUMP

62 years old | Married | Court reporter

Loves the fast pace and dedication required for her job
Needs a pump that will allow her to maintain a professional image in court

WHERE MIRANDA WAS BEFORE

Improved to intermediate-risk status since diagnosis 2 years ago^1,2
Taking IV Remodulin as part of a combination therapy regimen³
Concerned about the risk of bloodstream infection with IV therapy⁴
Declined SC Remodulin previously because she was afraid of infusion site pain

HOW MIRANDA AND HER PAH SPECIALIST SUCCESSFULLY TRANSITIONED HER TO SC REMODULIN

Discussed the safety features of the Remunity pump
Implemented a transition protocol to the Remunity pump
Maintained an appropriate dose escalation plan based on the bioequivalence of SC and IV Remodulin^4,5*
Collaborated on a proactive side effect management plan to help address AEs, including site pain

WHERE MIRANDA IS NOW

My doctor made sure I was prepared for the possibility of infusion site pain, so I picked a site on my stomach and followed our plan for pain.⁶ The Remunity pump is much smaller than the CADD-Legacy^® 1 PCA Ambulatory Infusion pump. No one in court even knows I’m wearing it!

—Miranda

Learn more about Remunity.

Learn more

AE=adverse event; IV=intravenous; PAH=pulmonary arterial hypertension; SC=subcutaneous.

JULIA – WANTING A SIMPLE PUMP

38 years old | Married | Financial analyst

Busy professional with children looking for ways to simplify her day
Wants to take her children to the neighborhood pool without worrying about her pump

WHERE JULIA WAS BEFORE

Diagnosed with PAH 4 years ago
Taking SC Remodulin for 9 months as part of treatment plan¹
Improved risk status after initiating Remodulin^1-3

HOW JULIA AND HER PAH SPECIALIST WORKED TOWARD HER GOALS TOGETHER

They discussed how the Remunity pump may simplify Julia’s treatment management
Julia switched to the Remunity pump because it’s easier to refill and more discreet

WHERE JULIA IS NOW

I’m impressed by how easy the Remunity Pump is to use. I love that the cassette is prefilled—I just need to prime it and twist to lock it to my pump. Knowing my pump is water-resistant* and easy to check with the remote lets me concentrate on other things at the pool, like keeping an eye on my energetic kids!

—Julia

*Remunity is watertight to a depth of 8 feet for 30 minutes or 12 feet for 3 minutes.

Learn more about Remunity.

Learn more

PAH=pulmonary arterial hypertension; SC=subcutaneous.

CLARENCE – NEEDING A SMALL, DISCREET PUMP

56 years old | Single | Local meteorologist

Spends much of his day in a news studio
Worries about his pump being visible on camera

WHERE CLARENCE WAS BEFORE

Categorized as intermediate-risk status at diagnosis last year^1,2
Despite the current therapy regimen, his 6MWD declined and his NT-proBNP levels have risen significantly from baseline
Declined parenteral therapy in the past due to concerns over pump size and obtrusiveness

HOW CLARENCE’S PAH SPECIALIST INCORPORATED SC REMODULIN INTO HIS ROUTINE

Proposed the smaller, more portable Remunity pump and counseled Clarence on ways to conceal his pump during work
Explained common AEs to Clarence and created a proactive management plan to help address them

WHERE CLARENCE IS NOW

I was worried people would think I wasn’t able to do my job. The Remunity pump is small enough that I can easily hide it under my clothes and check it with my remote. Having the remote near me rather than attached to my catheter is convenient and more discreet.³

—Clarence

Learn more about Remunity.

Learn more

6MWD=6-minute walk distance; AE=adverse event; NT-proBNP=N-terminal pro–B-type natriuretic peptide; PAH=pulmonary arterial hypertension; SC=subcutaneous.

See the difference of nearly 2 decades of experience with remodulin

Important Safety Information

Warnings and Precautions

Chronic intravenous (IV) infusions of Remodulin delivered using an external infusion pump with an indwelling central venous catheter are associated with the risk of blood stream infections (BSIs) and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion is the preferred mode of administration.
Avoid abrupt withdrawal or sudden large reductions in dosage of Remodulin, which may result in worsening of PAH symptoms.
Titrate slowly in patients with hepatic or renal insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic or renal function.
Remodulin is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, treatment with Remodulin may produce symptomatic hypotension.
Remodulin inhibits platelet aggregation and increases the risk of bleeding.

Adverse Reactions

In clinical studies of SC Remodulin infusion, the most common adverse events reported were infusion site pain and infusion site reaction (redness, swelling, and rash). These symptoms were sometimes severe and sometimes required treatment with narcotics or discontinuation of Remodulin. The IV infusion of Remodulin with an external infusion pump has been associated with a risk of blood stream infections, arm swelling, paresthesias, hematoma, and pain. Other common adverse events (≥3% more than placebo) seen with either SC or IV Remodulin were headache (27% vs. 23%), diarrhea (25% vs. 16%), nausea (22% vs. 18%), rash (14% vs. 11%), jaw pain (13% vs. 5%), vasodilatation (11% vs. 5%), edema (9% vs. 3%), and hypotension (4% vs. 2%).

Drug Interactions

Remodulin dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.

Specific Populations

In patients with mild or moderate hepatic insufficiency, decrease the initial dose of Remodulin to 0.625 ng/kg/min of ideal body weight, and monitor closely. Remodulin has not been studied in patients with severe hepatic insufficiency.
Safety and effectiveness of Remodulin in pediatric patients have not been established.
It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients.
There are no adequate and well-controlled studies with Remodulin in pregnant women. It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.

Indication

Remodulin is a prostacyclin vasodilator indicated for the treatment of pulmonary arterial hypertension (PAH; WHO Group 1) to diminish symptoms associated with exercise. Studies establishing effectiveness included patients with NYHA Functional Class II-IV symptoms and etiologies of idiopathic or heritable PAH (58%), PAH associated with congenital systemic-to-pulmonary shunts (23%), or PAH associated with connective tissue diseases (19%).

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

Important Safety Information

Warnings and Precautions

Chronic intravenous (IV) infusions of Remodulin delivered using an external infusion pump with an indwelling central venous catheter are associated with the risk of blood stream infections (BSIs) and sepsis, which may be fatal. Therefore, continuous subcutaneous (SC) infusion is the preferred mode of administration.
Avoid abrupt withdrawal or sudden large reductions in dosage of Remodulin, which may result in worsening of PAH symptoms.
Titrate slowly in patients with hepatic or renal insufficiency, because such patients will likely be exposed to greater systemic concentrations relative to patients with normal hepatic or renal function.
Remodulin is a pulmonary and systemic vasodilator. In patients with low systemic arterial pressure, treatment with Remodulin may produce symptomatic hypotension.
Remodulin inhibits platelet aggregation and increases the risk of bleeding.

Adverse Reactions

In clinical studies of SC Remodulin infusion, the most common adverse events reported were infusion site pain and infusion site reaction (redness, swelling, and rash). These symptoms were sometimes severe and sometimes required treatment with narcotics or discontinuation of Remodulin. The IV infusion of Remodulin with an external infusion pump has been associated with a risk of blood stream infections, arm swelling, paresthesias, hematoma, and pain. Other common adverse events (≥3% more than placebo) seen with either SC or IV Remodulin were headache (27% vs. 23%), diarrhea (25% vs. 16%), nausea (22% vs. 18%), rash (14% vs. 11%), jaw pain (13% vs. 5%), vasodilatation (11% vs. 5%), edema (9% vs. 3%), and hypotension (4% vs. 2%).

Drug Interactions

Remodulin dosage adjustment may be necessary if inhibitors or inducers of CYP2C8 are added or withdrawn.

Specific Populations

In patients with mild or moderate hepatic insufficiency, decrease the initial dose of Remodulin to 0.625 ng/kg/min of ideal body weight, and monitor closely. Remodulin has not been studied in patients with severe hepatic insufficiency.
Safety and effectiveness of Remodulin in pediatric patients have not been established.
It is unknown if geriatric patients respond differently than younger patients. Caution should be used when selecting a dose for geriatric patients.
There are no adequate and well-controlled studies with Remodulin in pregnant women. It is not known whether treprostinil is excreted in human milk or if it affects the breastfed infant or milk production.

Indication

In patients with PAH requiring transition from epoprostenol, Remodulin is indicated to diminish the rate of clinical deterioration. Consider the risks and benefits of each drug prior to transition.

REMISIhcpOct19

Please see accompanying Full Prescribing Information for Remodulin.

For additional information, visit www.remodulin.com or call Customer Service Line at 1-877-UNITHER (1-877-864-8437).

GAIL—References: 1. Benza RL, Gomberg-Maitland M, Elliott CG, et al. Predicting survival in patients with pulmonary arterial hypertension: the REVEAL risk score calculator 2.0 and comparison with ESC/ERS-based risk assessment strategies. Chest. 2019;156(2):323-337. 2. Galiè N, Humbert M, Vachiery JL, et al; ESC Scientific Document Group. 2015 ESC/ERS guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2016;37(1):67-119. 3. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. 4. Remodulin [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2018. 5. Guidepoint Global, LLC. Patient volume data, last verified December 2019. 6. Lang I, Gomez-Sanchez M, Kneussl M, et al. Efficacy of long-term subcutaneous treprostinil sodium therapy in pulmonary hypertension. Chest. 2006;129(6):1636-1643. 7. White RJ, Levin Y, Wessman K, et al. Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics. Pulm Circ. 2013;3(3):611-621. 8. Mathier MA, McDevitt S, Saggar R. Subcutaneous treprostinil in pulmonary arterial hypertension: practical considerations. J Heart Lung Transplant. 2010;29(11):1210-1217.

CHARLOTTE—References: 1. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. 2. Remodulin [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2018. 3. Laliberte K, Arneson C, Jeffs R, et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin^®) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004;44(2):209-214. 4. Benza RL, Gomberg-Maitland M, Naeije R, et al. Prognostic factors associated with increased survival in patients with pulmonary arterial hypertension treated with subcutaneous treprostinil in randomized, placebo-controlled trials. J Heart Lung Transplant. 2011;30(9):982-989. 5. White RJ, Levin Y, Wessman K, et al. Subcutaneous treprostinil is well tolerated with infrequent site changes and analgesics. Pulm Circ. 2013;3(3):611-621. 6. Mathier MA, McDevitt S, Saggar R. Subcutaneous treprostinil in pulmonary arterial hypertension: practical considerations. J Heart Lung Transplant. 2010;29(11):1210-1217.

MIRANDA—References: 1. Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175-4181. 2. Galiè N, Humbert M, Vachiery JL, et al; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2016;37(1):67-119. 3. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. doi:10.1183/13993003.01889-2018 4. Remodulin [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2018. 5. Laliberte K, Arneson C, Jeffs R, et al. Pharmacokinetics and steady-state bioequivalence of treprostinil sodium (Remodulin^®) administered by the intravenous and subcutaneous route to normal volunteers. J Cardiovasc Pharmacol. 2004;44(2):209-214. 6. Mathier MA, McDevitt S, Saggar R. Subcutaneous treprostinil in pulmonary arterial hypertension: practical considerations. J Heart Lung Transplant. 2010;29(11):1210-1217.

JULIA—References: 1. Galiè N, Channick RN, Frantz RP, et al. Risk stratification and medical therapy of pulmonary arterial hypertension. Eur Respir J. 2019;53(1):1801889. doi:10.1183/13993003.01889-2018 2. Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175-4181. 3. Galiè N, Humbert M, Vachiery JL, et al; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2016;37(1):67-119.

CLARENCE—References: 1. Kylhammar D, Kjellström B, Hjalmarsson C, et al. A comprehensive risk stratification at early follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart J. 2018;39(47):4175-4181. 2. Galiè N, Humbert M, Vachiery JL, et al; ESC Scientific Document Group. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: the Joint Task Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society (ERS). Eur Heart J. 2016;37(1):67-119. 3. Remodulin [package insert]. Research Triangle Park, NC: United Therapeutics Corporation; 2018.

Patient Profiles—Planning For Success

Gail – Reaching Optimal Dose

63 years old | Married | Cafeteria worker

Find out how Gail reached her optimal dose

Charlotte – Switching From IV To SC

47 years old | Divorced | Small business owner

Learn More About AE Management Strategies

HOW THE REMUNITY® PUMP FITS INTO PATIENTS’ LIVES

MIRANDA – LOOKING FOR A SAFE, MODERN PUMP

62 years old | Married | Court reporter

LEARN ABOUT MIRANDA’S TRANSITION TO REMUNITY

JULIA – WANTING A SIMPLE PUMP

38 years old | Married | Financial analyst

DISCOVER HOW JULIA SIMPLIFIED HER TREATMENT REGIMEN

CLARENCE – NEEDING A SMALL, DISCREET PUMP

56 years old | Single | Local meteorologist

FIND OUT HOW CLARENCE DISCREETLY CONTROLLED HIS PUMP

HOW THE REMUNITY^® PUMP FITS INTO PATIENTS’ LIVES